IMMUNITYBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
IMMUNITYBIO, INC. (IBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $5.13 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.19, a 4.24% decline year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.42, a 0.18% decline year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.43, a 6.86% decline year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.83, a 13.42% increase year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $16.05, a 192.88% increase from fiscal 2024.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $5.48, a 0.90% decline from fiscal 2023.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $5.53, a 6.43% decline from fiscal 2022.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $5.91, a 41.49% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.13 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $5.19 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $16.05 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $19.82 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $5.15 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $5.42 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $5.48 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $5.46 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $5.44 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $5.43 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $5.53 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $5.48 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $5.30 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $5.83 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $5.91 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $5.95 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $6.02 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $5.14 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $10.10 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $10.07 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |